• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Diabetic Retinopathy - Pipeline Review, H2 2013 - Product Image

Diabetic Retinopathy - Pipeline Review, H2 2013

  • Published: September 2013
  • 150 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Acucela Inc.
  • BioDiem Ltd
  • EyeGene, Inc.
  • Novagali Pharma SA
  • PanOptica, Inc.
  • R-Tech Ueno, Ltd.
  • MORE

Diabetic Retinopathy - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Diabetic Retinopathy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Retinopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy. Diabetic Retinopathy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Diabetic Retinopathy.
- A review of the Diabetic Retinopathy products under development by companies and universities/research READ MORE >

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Diabetic Retinopathy Overview
Therapeutics Development
An Overview of Pipeline Products for Diabetic Retinopathy
Diabetic Retinopathy Therapeutics under Development by Companies
Diabetic Retinopathy Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Diabetic Retinopathy Therapeutics - Products under Development by Companies
Diabetic Retinopathy Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Diabetic Retinopathy Therapeutics Development
Oxford BioMedica plc
Novagali Pharma SA
Antisense Therapeutics Limited
Lpath, Inc.
BioDiem Ltd
RegeneRx Biopharmaceuticals, Inc.
ThromboGenics NV
R-Tech Ueno, Ltd.
Paloma Pharmaceuticals, Inc.
Acucela Inc.
OcuCure Therapeutics, Inc.
Gene Signal International SA.
Promedior, Inc.
Inotek Pharmaceuticals Corporation
Angstrom Pharmaceuticals, Inc.
FirstString Research, Inc.
Sirnaomics, Inc.
Resolvyx Pharmaceuticals, Inc
Stelic Institute & Co.
Centocor Ortho Biotech, Inc.
EyeCyte, Inc.
Vascular Pharmaceuticals, Inc.
PanOptica, Inc.
Targa Therapeutics Corp.
EyeGene, Inc.
America Stem Cell, Inc.
Ampio Pharmaceuticals, Inc.
Diabetic Retinopathy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ATL-1103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
iSONEP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DG-3173 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VCM For Diabetic Retinopathy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ocriplasmin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RGN-259 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PARP Inhibitors - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INO-6001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DT-23552 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STNM-1510 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RX-20001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OC-10X - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Granzyme B/VEGF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
A-6 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aganirsen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P-529 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
danazol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MTP-131 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AKB-9778 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BDM-E - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RTU-007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GLY-230 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
A-717 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MS-553 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STP-601 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VEGF/rGel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PAN-90806 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EG-Mirotin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FP-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IB-09A0133 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INO-6002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Age-Related Macular Degeneration And Diabetic Retinopathy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VPI-2690-B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy For Diabetic Complications - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VPI-2690-B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neuregulins - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Diabetic Neuropathy And Retinopathy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASC-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V-1932 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EC-301 Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EC-200 Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C16Y Peptide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Diabetic Retinopathy Therapeutics - Drug Profile Updates
Diabetic Retinopathy Therapeutics - Discontinued Products
Diabetic Retinopathy Therapeutics - Dormant Products
Diabetic Retinopathy - Product Development Milestones
Featured News & Press Releases
Jun 03, 2013: Oxford BioMedic Voluntarily Pauses Recruitment Into Phase I Study Of RetinoStat
May 07, 2012: Promedior Presents Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting
May 01, 2012: Promedior To Present Data From Preclinical Studies Of Pentraxin-2 At ARVO Annual Meeting
May 01, 2012: Promedior To Present Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting
Apr 27, 2012: Ampio Receives US And Canadian Notice Of Allowance Of Patents For Optina
Mar 19, 2012: Ampio Announces Positive Preliminary Update On Optina Clinical Trial To Treat Diabetic Macular Edema
Feb 09, 2012: Antisense Therapeutics Provides Development Update On ATL1103
Dec 07, 2011: Antisense Therapeutics's ATL1103 Successfully Progresses Towards Phase II Clinical Trial
Nov 21, 2011: Akebia Initiates Phase I Study Of HPTPß Inhibitor For Diabetic Macular Edema And Diabetic Retinopathy
Nov 07, 2011: ANP Receives Japanese Patent For ATL1103
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Diabetic Retinopathy, H2 2013
Products under Development for Diabetic Retinopathy - Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Number of Products under Development by Companies, H2 2013 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2013
Comparative Analysis by Late Stage Development, H2 2013
Comparative Analysis by Mid Clinical Stage Development, H2 2013
Comparative Analysis by Early Clinical Stage Development, H2 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013
Products under Development by Companies, H2 2013
Products under Development by Companies, H2 2013 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2013
Oxford BioMedica plc, H2 2013
Novagali Pharma SA, H2 2013
Antisense Therapeutics Limited, H2 2013
Lpath, Inc., H2 2013
BioDiem Ltd, H2 2013
RegeneRx Biopharmaceuticals, Inc., H2 2013
ThromboGenics NV, H2 2013
R-Tech Ueno, Ltd., H2 2013
Paloma Pharmaceuticals, Inc., H2 2013
Acucela Inc., H2 2013
OcuCure Therapeutics, Inc., H2 2013
Gene Signal International SA., H2 2013
Promedior, Inc., H2 2013
Inotek Pharmaceuticals Corporation, H2 2013
Angstrom Pharmaceuticals, Inc., H2 2013
FirstString Research, Inc., H2 2013
Sirnaomics, Inc., H2 2013
Resolvyx Pharmaceuticals, Inc, H2 2013
Stelic Institute & Co., H2 2013
Centocor Ortho Biotech, Inc., H2 2013
EyeCyte, Inc., H2 2013
Vascular Pharmaceuticals, Inc., H2 2013
PanOptica, Inc., H2 2013
Targa Therapeutics Corp., H2 2013
EyeGene, Inc., H2 2013
America Stem Cell, Inc., H2 2013
Ampio Pharmaceuticals, Inc., H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Stage and Molecule Type, H2 2013
Diabetic Retinopathy Therapeutics - Drug Profile Updates
Diabetic Retinopathy Therapeutics - Discontinued Products
Diabetic Retinopathy Therapeutics - Dormant Products

List of Figures
Number of Products under Development for Diabetic Retinopathy, H2 2013
Products under Development for Diabetic Retinopathy - Comparative Analysis, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Late Stage Products, H2 2013
Mid Clinical Stage Products, H2 2013
Early Clinical Stage Products, H2 2013
Discovery and Pre-Clinical Stage Products, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Route of Administration, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Molecule Type, H2 2013
Assessment by Stage and Molecule Type, H2 2013 56

Oxford BioMedica plc
Novagali Pharma SA
Antisense Therapeutics Limited
Lpath, Inc.
BioDiem Ltd
RegeneRx Biopharmaceuticals, Inc.
ThromboGenics NV
R-Tech Ueno, Ltd.
Paloma Pharmaceuticals, Inc.
Acucela Inc.
OcuCure Therapeutics, Inc.
Gene Signal International SA.
Promedior, Inc.
Inotek Pharmaceuticals Corporation
Angstrom Pharmaceuticals, Inc.
FirstString Research, Inc.
Sirnaomics, Inc.
Resolvyx Pharmaceuticals, Inc
Stelic Institute & Co.
Centocor Ortho Biotech, Inc.
EyeCyte, Inc.
Vascular Pharmaceuticals, Inc.
PanOptica, Inc.
Targa Therapeutics Corp.
EyeGene, Inc.
America Stem Cell, Inc.
Ampio Pharmaceuticals, Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos